Enterprise Learning Strategy and Operational Launch Support
Overview
Buyer
Place of Performance
NAICS
PSC
Set Aside
Original Source
Timeline
Qualification Details
Fit reasons
- NAICS alignment with historical contract wins in similar service areas.
- Scope strongly matches core technical capabilities and delivery model.
Risks
- Past performance thresholds may require one additional teaming partner.
- Potential clarification needed on staffing minimums before bid/no-bid.
Next steps
Validate eligibility requirements, assign capture owner, and schedule partner outreach to confirm teaming strategy before submission planning.
Quick Summary
The Food and Drug Administration (FDA), specifically the Office of Human Capital Management (OHCM), is seeking contractor assistance for Enterprise Learning Strategy and Operational Launch Support. This Presolicitation aims to transition the FDA towards a more coordinated enterprise learning model. Responses are due July 2, 2026.
Scope of Work
The contractor will support FDA's OHCM in transitioning from independently managed learning activities by various Centers, Offices, and Programs (COPs) to a centralized, coordinated enterprise learning model. Key tasks include:
- Evaluating current learning programs across the Agency.
- Developing structured frameworks for enterprise learning management.
- Establishing governance models to ensure consistency and alignment.
- Creating operational processes to support the new enterprise learning system.
The goal is to improve efficiency, reduce duplication, and align learning and development activities with federal workforce policies and Agency priorities.
Contract & Timeline
- Type: Presolicitation
- Product/Service Code: U009 (Education Services)
- Set-Aside: None specified
- Response Due: July 2, 2026, 6:00 PM ET
- Published: June 17, 2026
Additional Notes
This notice is a presolicitation, indicating that a formal solicitation or request for proposals is expected to follow. It serves to inform potential bidders of an upcoming opportunity. Interested parties should monitor SAM.gov for future updates and the release of the official solicitation document.
Contact Information
- Primary: Amanda Lusk (Amanda.Lusk@fda.hhs.gov)
- Secondary: Nicholas Bisher (Nicholas.Bisher@fda.hhs.gov)